Survival of high-risk pediatric neuroblastoma patients in a developing country

Joseph C Easton1,2, Sergio Gomez3, Peter H Asdahl4

  • 1Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.

Insights

Survival for high-risk pediatric neuroblastoma is poor globally. However, survival rates in developing countries like Argentina are dramatically worse, highlighting critical needs for improved treatment and supportive care.

Area of Science:

  • Pediatric Oncology
  • Global Health
  • Cancer Epidemiology

Background:

  • Limited data exists on high-risk neuroblastoma patient survival in developing nations.
  • Assessing survival disparities is crucial for global pediatric cancer care.

Purpose of the Study:

  • To evaluate survival outcomes for high-risk pediatric neuroblastoma patients in La Plata, Argentina.
  • To compare survival rates with those reported in developed countries.

Main Methods:

  • Retrospective cohort study of 39 high-risk neuroblastoma patients treated between 1999-2015.
  • Kaplan-Meier method used to estimate overall survival probabilities.

Main Results:

  • Median survival was 1.7 years.
  • Five-year overall survival probability was 24%, significantly lower than in developed countries (23-76%).
  • High-risk neuroblastoma survival is poor globally, but markedly worse in this developing country cohort.

Conclusions:

  • Pediatric neuroblastoma survival is poor in developing countries, underscoring significant global health inequities.
  • Improving treatment and supportive care, despite resource limitations, is essential to reduce survival gaps.